Lorus announces presentation of corporate overview at the Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conference
14 Mai 2007 - 3:30PM
PR Newswire (US)
- Presentation available by web cast - TORONTO, May 14
/PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. ("Lorus") (TSX:
LOR; AMEX: LRP), a biopharmaceutical company specializing in the
research and development of pharmaceutical products and
technologies for the management of cancer, today announced that Dr.
Aiping Young, President and CEO of Lorus, would provide a Company
update at the Rodman and Renshaw 4th Annual Global Healthcare
Conference. WHEN: May 14, 2007 WHERE: Zephyr Salon, 4th Floor Monte
Carlo, Monaco TIME: 11:10 a.m. CEST (Central European Summer Time)
Interested parties may gain access to a live audio webcast of the
presentation by visiting the Investor Relations section of Lorus'
website at http://www.wsw.com/webcast/rrshq11/lrp, which will be
available through the same location through May 14, 2007. Lorus is
one of over 300 invited companies to present at this conference
held from May 14 to 15, 2007. The conference provides informational
service and networking opportunities for healthcare companies and
investors. About Lorus Lorus is a biopharmaceutical company focused
on the research and development of novel therapeutics in cancer.
Lorus' goal is to capitalize on its research, preclinical, clinical
and regulatory expertise by developing new drug candidates that can
be used, either alone, or in combination with other drugs, to
successfully manage cancer. Through its own discovery efforts and
an acquisition and in-licensing program, Lorus is building a
portfolio of promising anticancer drugs. Lorus has several product
candidates in multiple Phase II clinical trials and has completed
one Phase II and one Phase III clinical trial. Lorus Therapeutics
Inc. is listed on the Toronto Stock Exchange under the symbol LOR,
and on the American Stock Exchange under the symbol LRP.
Forward-looking statements This press release may contain
forward-looking statements within the meaning of Canadian and U.S.
securities laws. Such statements include, but are not limited to,
statements relating to: our research program plans, our plans to
conduct clinical trials, the successful and timely completion of
clinical studies and the regulatory approval process, our ability
to fund future research, our plans to obtain partners to assist in
the further development of our product candidates, the
establishment of corporate alliances, the Company's plans,
objectives, expectations and intentions and other statements
including words such as "continue", "believe", "plan", "expect",
"intend", "will", "should", "may", and other similar expressions.
Such statements reflect our current views with respect to future
events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance, or achievements
that may be expressed or implied by such forward-looking
statements, including, among others: our ability to obtain the
capital required for research and operations, the inherent risks in
early stage drug development including demonstrating efficacy,
development time/cost and the regulatory approval process; the
progress of our clinical trials; our ability to find and enter into
agreements with potential partners; our ability to attract and
retain key personnel; changing market conditions; and other risks
detailed from time-to-time in our ongoing quarterly filings, annual
information forms, annual reports and annual filings with Canadian
securities regulators and the United States Securities and Exchange
Commission. Should one or more of these risks or uncertainties
materialize, or should the assumptions set out in the section
entitled "Risk Factors" in our Annual Information Form underlying
those forward-looking statements prove incorrect, actual results
may vary materially from those described herein. These
forward-looking statements are made as of the date of this press
release and we do not intend, and do not assume any obligation, to
update these forward-looking statements, except as required by law.
We cannot assure you that such statements will prove to be accurate
as actual results and future events could differ materially from
those anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein. Lorus Therapeutics Inc.'s recent press releases are
available through the Company's website at
http://www.lorusthera.com/. DATASOURCE: Lorus Therapeutics Inc.
CONTACT: Lorus Therapeutics Inc., Dr. Saeid Babaei, (416) 798-1200
ext. 490,
Copyright